tbuckley/cabot-search huggingface dataset:
Insulin-like growth factors in the blood of patients with oral squamous cell carcinoma receiving therapy with monoclonal antibodies (cetuximab).
Authors: Aza A. Lyanova, Elena M. Frantsiyants, Liubov Yu Vladimirova, Irina V. Neskubina, Ekaterina I. Surikova, Marina A. Engibaryan, Natalia A. Abramova, Irina L. Popova, Natalia M. Tikhanovskaya, Maria A. Teplyakova, Kristina A. Novoselova, Ludmila A. Ryadinskaya, Valeriya S Myagkova, Yuriy A. Fomenko, Oleg I. Kit
Journal: Journal of Clinical Oncology (2020)

e18564 Background: IGF-1 and IGF-2 are powerful mitogenic factors with anti-apoptotic effect. Their overproduction leads to neoangiogenesis and metastasis. Monitoring the level of these factors can serve as a potential predictive tool. The purpose of the study was to study blood levels of IGF-1 and IGF-2 in patients with squamous cell carcinoma (SCC) of the oral cavity depending of the efficacy of chemotherapy (CT) and cetuximab. Methods: The study included 50 patients with squamous cell carcinoma of the oral cavity T3-4N0-1M0, stage III-IV. The main group (n = 30) received 2 CT cycles with cetuximab: cisplatin 100 mg/m 2 , intravenously, day 1, 5-fluorouracil 1000 mg/m 2 /day, intravenously, 96-hour continuous infusion, in combination with cetuximab 400 mg/m2 on day 1 in a loading dose, then 250 mg/m2 on days 8 and 15. The control group (n = 20) received 2 CT cycles: intravenous cisplatin 100 mg/m 2 on day 1, intravenous 5-fluorouracil 1000 mg/m 2 /day, 96-hour continuous infusion on days 1-4. Results were compared with the values in 20 non-cancer donors. Levels of IGF-1 (mcg/L) and IGF-2 (ng/mL) were measured in the blood serum by ELISA using standard test systems (Mediagnost, Germany). Statistical analysis of results was performed using the Statistica 6.0 program (Stat-Soft, 2001). Results: Before treatment, levels of IGF-1 and IGF-2 in patients were lower than in donors by 53.5% and 20.3%, respectively. In patients with partial regression after CT, IGF-1 levels significantly increased by 33% (p &lt; 0,05), compared to the values before treatment, while IGF-2 was both within donor and initial values and the IGF-1/IGF-2 ratio was similar to the initial level but 33.3% lower than in donors. The patients in the main group with partial regression normalized IGF-1 levels increasing it compared to initial values – by 87%. IGF-2 levels did not differ statistically significantly from the initial values and were 32.5% lower than in donors. The IGF-1/IGF-2 ratio was 58% higher than before treatment. Conclusions: CT and cetuximab normalized blood levels of IGF-1 in oral cancer patients with partial tumor regression.
An analysis for related factors influencing urinary ratio of albumin to creatinine in patients with type-2 diabetics
Authors: 王海鹰, 蔡蓉, 刘文斌, 葛军, 王宝珍, 史京衡, 史虹莉
Journal: BMJ (2005)

目的 研究2型糖尿病患者血压、血脂、糖化血红蛋白(HbA1c)、体重指数(BMI)、体重等对尿白蛋白/肌酐的影响.方法对538名2型糖尿病患者采血、留取晨尿,分别测定其空腹血糖、血脂、HbA1c、晨尿白蛋白(Alb)、肌酐(Cr),计算Alb/Cr(mg/mmol),测量身高、体重、坐位血压.分别将患者分为高血压和非高血压组(177和361例)、肥胖和非肥胖组(181和357例)、高胆固醇组与正常胆固醇组(108和430例),分析血压、血脂、BMI 、HbA1c与尿Alb/Cr的关系.结果 Alb/Cr与收缩压、体重、BMI相关(P 0.05).结论尿Alb/Cr值与高血压、肥胖等因素相关,是否受年龄、血脂等的影响尚待进一步探讨,高血压、肥胖可能是2型糖尿病患者发生糖尿病肾病的高危因素。
Feedback from trainees and trainers of interactive clinical skill training workshop for general practice
Authors: Yue Sha, Xuejun Zeng, Zhong He
Journal: BMJ (2015)

Objective
To review the feedback from trainees and trainers of interactive clinical skill training workshop for general practice.


Methods
An interactive clinical training workshop was held on October, 2014, medical staff from 17 provinces or municipalities attended the workshop.Feedback from 86 trainees was collected by questionnaire survey, while the feedback from 12 trainers was collected by focus group.


Results
Total 86 questionnaires were collected from trainees with a response rate of 100%.The average working year of trainees was 15.6; 38.4% of them were general practitioners in community health centers; and most of them had no similar trainings before.Among 86 trainees, 70 (81.4%) thought that the training contents were relevant to their daily work, 76 (88.4%) thought that workshop was good method for the training.More than 55.0% trainees told that the training contents met their expectation; 76 (88.4%) thought that the workshop was well conducted in general, 68 (79.1%) were willing to participate similar training workshops in the future.However, the contentsprobably need similar trainingadvised by the trainers in the questionnaire were not agreed by trainees.The trainers thought the width and depth of training contents should be modified according to the trainees' level.Basic knowledge, basic clinical skill and common diseases should be emphasized; and the concept of general practice and indications of referral were among the important but difficult parts in the training.For an interactive clinical skill training, teaching materials preparation, lacale control and local teaching facilities were all important.


Conclusions
Clinical skill training is an important part of general practitioners' training, and workshop is an effective way for training.The training contentd should be more closer to the daily work of general practitioners.


Key words: 
Clinical skills; Teaching; Questionnaires; Focus group; General practitioners
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
Authors: Valentina Boni, Howard A. Burris III, Joyce F. Liu, Alexander I. Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Lee S. Rosen, Randy F. Sweis, Nataliya Volodymyrivna Uboha, Rachel E. Sanborn, Bert O'Neil, James J. Harding, Patricia LoRusso, Amy M. Weise, Javier Garcia-Corbacho, Iván Victoria, John W. Frye, Rachel Li, Mark Stroh, Funda Meric-Bernstam
Journal: Journal of Clinical Oncology (2020)

526 Background: CX-2009 is a PROBODY drug conjugate (PDC) directed against CD166 (ALCAM) and conjugated to DM4, a potent microtubule inhibitor (MTI). CD166 is overexpressed in carcinomas but is also ubiquitously expressed in normal epithelium and thus has not been previously considered a viable target for a traditional antibody drug conjugate. PDCs have a peptide mask that blocks normal tissue binding and can be removed by tumor-associated proteases, thereby limiting off-tumor/on-target binding. CX-2009 demonstrated preclinical activity in multiple solid tumor models. Here we report results of the first in human study in patients with advanced cancer. Methods: In this phase I multi-part dose-escalation study, pts with advanced solid tumors received CX-2009 0.25–10 mpk IV every 14 or 21 days (Q2W or Q3W). Tumor types were selected based on expected high CD166 expression and MTI sensitivity. Results: The dose-escalation phase of the trial enrolled 43 pts; 49 additional pts were subsequently enrolled between 4–10 mpk to collect biomarker data and define the recommended phase II dose (RP2D), for a total of 92 pts as of 30 Nov 2019 (39 pts with breast cancer [BC], 22 ovarian [OC], 12 non-small cell lung [NSCLC], 9 head/neck squamous cell [HNSCC], 10 other) with a median of 6 (range 1–19) prior therapies. Median number of CX-2009 doses was 2 (range, 1–15). For Q3W dosing, one dose limiting toxicity (DLT; grade 3 vomiting) was observed at 8 mpk; MTD was not reached up to 10 mpk. The RP2D for Q3W schedule was 7 mpk based on safety, dose-response, and population pharmacokinetic simulations. Q2W dosing continues; DLTs were observed at 6 mpk. Common treatment-related adverse events (TRAEs) at 7 mpk (n=9) were nausea (44%), fatigue, infusion-related reactions (both 33%), vomiting and arthralgias (both 22%). Grade 3 TRAEs occurred in 2 pts (nausea/vomiting; peripheral neuropathy). No pts discontinued at 7 mpk due to TRAEs. Ocular toxicity was dose dependent; mild to moderate reversible keratitis/blurred vision was seen in 3 pts at 7 mpk and mitigated by ocular prophylaxis. Partial responses were seen in 8 pts (2 confirmed, both HR+/HER2- BC) treated between 4–10 mpk, including BC (n=5), OC (n=2), and HNSCC (n=1). SD (≥1 on-study scan) was observed in 21 pts, 5 had SD ≥3 mos. Conclusions: CX-2009 at 7 mpk is the RP2D on Q3W schedule. Phase II expansion has begun in pts with HR+/HER2- BC. The Q2W schedule will continue to enroll pts to define the RP2D. CX-2009 will also be studied in combination with CX-072, a PD-L1 PROBODY therapeutic ( NCT03149549 ) Clinical trial information: NCT03149549 .
The nature and management of acquired resistance to PD1-based therapy in melanoma.
Authors: Adriana Hepner, Judith M. Versluis, Camille Lea Gerard, Lauren Julia Brown, Roslyn Wallace, Prachi Bhave, Yanina Jansen, Oliver Klein, Allison Betof Warner, Joanna Mangana, Victoria Atkinson, Serigne Lo, Georgina V. Long, Douglas Buckner Johnson, Jennifer Leigh McQuade, Paolo Antonio Ascierto, Lisa Zimmer, Celeste Lebbe, Christian U. Blank, Alexander M. Menzies
Journal: Journal of Clinical Oncology (2020)

10014 Background: Anti-PD1 therapy (PD1), either alone or in combination with anti-CTLA4, has high initial response rates, but 20% of patients (pts) with complete response (CR) and 60% with partial response (PR) experience disease progression by 5 years. The nature and best management of this acquired resistance (AR) remains unknown. Methods: Consecutive pts from 16 centers who achieved CR or PR to PD1-based therapy and who later progressed were examined. Demographics, disease characteristics, nature of progression and subsequent treatments were examined. Results: 300 pts were identified, median age was 64y, 133 (44%) BRAF mutant and 55 (18%) had target therapy (TT) prior to PD1-based therapy. 173 (58%) received PD1 alone, 114 (38%) PD1+CTLA4 and 13 (4%) PD1 + an investigational drug. 89 (30%) pts had CR, 210 (70%) pts had PR. Median time to AR was 12.6 mo (95% CI, 11.3, 14.2) and 142 (47%) progressed while still on drug. Most pts (N = 194, 65%) progressed in a single organ site, and in a solitary lesion (N = 154, 51%). 38 (25%) progressed in the brain only. AR was in new lesion in 136 (45%), existing lesions in 106 (35%), and both new and existing lesions in 58 (19%). For those with solitary lesion progression, 51 (33%) had local (L) treatment alone, 54 (35%) had local and systemic (L+ST), 46 (30%) had systemic therapy alone (ST) and 3 (2%) had no further treatment (BSC). If progression was non-solitary, 89 (61%) had ST, 33 (23%) L+ST, 17 (12%) L alone and 7 (5%) BSC. For those who received ST after AR, first ST (ST1) was PD1 alone in 130 (51%) [53, 41% continuation, 77, 59% reinduction], PD1+CTLA4 in 31 (12%), CTLA4 alone in 15 (6%), targeted therapy in 49 (19%) and investigational drugs in 29 (11%). Median follow-up from AR was 20 mo (95% CI 18-22). The ORR to ST1 was 46% for PD1 alone (56% continuation, 42% reinduction), 56% for PD1+ CTLA4, 0% for CTLA4 alone, 20% for investigational drugs and 67% for TT. Median OS from AR was 38 mo (95% CI, 34.6-NR). 2y-OS was 69% in those with solitary progression compared to 55% for the pts that had a non-solitary progression (p &lt; 0.001). There was no difference in OS by ST1 class. Detailed analyses including nature and management of AR while on PD1 or after discontinuation will be presented, as will site-specific AR outcomes. Conclusions: Acquired resistance to PD1-based therapy in melanoma is usually oligometastatic, occurring approximately one year after PD1 start. Most pts with isolated progression have local therapy, and the most frequent subsequent systemic therapy is PD1-alone. Patients with AR can have meaningful survival, with median OS over 3 years from AR.
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
Authors: JosE GarcIa SAnchez, Marta Benet Gimenez, Lourdes Cordón, Maria De Julian, Marta Piqueras, Veronica Ruiz, Javier Garde, Nuria Piera, Alfredo Sanchez, David Lorente, Julian Carretero, Oscar Juan-Vidal, Agustin Lahoz
Journal: Journal of Clinical Oncology (2020)

e15042 Background: Inhibitors of immune checkpoint PD-1/PD-L1 (ICI) have become a care standard in non-small cell lung cancer (NSCLC). Despite promising results, some patients cannot take advantage of immunotherapy effects. Nowadays, neither predictive nor prognostic circulating biomarkers have been found in order to select patients or to predict response to ICI. Myeloid-derived suppressor cells (MDSC) are potent immunity suppressors and may represent both a potential prognostic and a predictive biomarker. We aimed to assess the role of pretreatment circulating MDSC subpopulations on ICI outcomes in NSCLC patients. Methods: 86 NSCLC patients treated with ICI and 10 healthy donors in 3 centers between 02/2018 and 10/2019 were eligible. Pretreatment immunophenotyping of monocytes, early-MDSC (e-MDSC: CD14-/CD15-/HLA-DR-/CD33+/CD11b+), monocytic-MDSC (M-MDSC: CD14+/CD15-/HLA-DR-/CD33+/CD11b+) and polymorphonuclear-MDSC (PMN-MDSC: CD14-/CD15+/HLA-DR-/CD33+/CD11b+) was prospectively performed by flow cytometry in fresh whole blood. Correlation between baseline circulating MDSC subpopulations and Neutrophils/Lymphocytes Ratio (NLR) was evaluated as well as their impact on outcomes. Results: 86 patients who received at least one previous platinum based combination chemotherapy for stage III-IV NSCLC were prospectively included; 82 (95%) smokers, median age 62 years; 52 (60%) non-squamous; 69 (93%) ECOG PS 0-1; 43 (50%) PDL1 ≥ 1% and 65 (76%) were treated in a second line setting. Median PFS (mPFS) was 2.79 months (m) [95% CI, 1.3-4.2] and mOS 11.6 m [9.3-13.9]. Overall, 3m-death rate was 18.6%. Pretreatment high-NLR (NLR &gt; 3) (62/86; 72%) was correlated with poor PFS (p = 0.03), OS (p = 0.01) and a 3m-death rate of 22.6%. High level of global MDSC before anti-PD-1/PD-L1 therapy, defined by the median value as a cut-off ( &gt; 6.3%), was associated with poor OS (p = 0.03). Pretreatment low e-MDSC ( &lt; 21.7%), were also associated with poor PFS (p = 0.01), OS (p = 0.006) and a 3m-death rate of 23.8%. There was not correlation between M-MDSC and PMN-MDSC and clinical outcomes. Conclusions: Our study suggests that a baseline circulating low level of e-MDSC and high-NLR are associated with early failure to ICI and poorer survival. The role of e-MDSC appears interesting as a potential predictive and prognostic biomarker in NSCLC patients treated with anti-PD1/PD-L1. Dynamic assessment of MDSC levels over time and further validation with longer follow up in larger cohorts are needed.
Helicobacter pylori infection in immediate relatives of patients with gastric cancer
Authors: Qun-ying Wang, Jian-sheng Li, Yun Xu
Journal: BMJ (2012)

Objective To investigate the Helicobacter pylori (Hp) infection in the immediate relatives of patients with gastric cancer.Methods One hundred and eighty two immediate relatives of 86patients with gastric cancer and 126 age and sex-matched immediate relatives of 46 dyspeptic patients were enrolled in the study from March 2010 to March 2011.C14 or C13 urea breath tests were performed and for those with Hp-positive results serological typing was further performed.Results One hundred and forty two out of 182 immediate relatives of gastric cancer patients were Hp positive with a Hp infection rate of 78％,which was significantly higher than that of immediate relatives of dyspeptic patients ( 78.0％ vs 47.6％,x2 =30.5,P ＜ 0.05,P =0.006 ).The average age of former was significantly higher than that of latter (46 ±6 y vs 38 ± 6 y; t =13.34,P ＜ 0.05).The rate of serological type Hp-1 in immediate relatives of cancer patients was significantly higher than that of those of dyspeptic patients (68.3％ vs 38.3％,x2 =14.28,P ＜0.05 ).The infection rate of children,both parents of whom were infected with Hp and only one parent infected with Hp (52.8％,43.2％,respectively ) was higher than that of children whose parents were not infected with Hp ( 13.3％ ) ( x2 =6.80,P ＜ 0.01 and x2 =4.35,P ＜ 0.05 ).Conclusions The Hp infection rate is high in immediate familial members of gastric cancer patients and the predominant serological type of Hp is Hp-1.

Key words: 
Helicobacter pylori ;  Stomach neoplasms;  Family
乙型肝炎病毒家庭内传播的社区调查分析
Authors: 侯春生, 闫香芹
Journal: BMJ (2004)

检测260例乙型肝炎病毒(HBV)感染者家庭成员的乙肝五项指标(HBV-M)和HBV-DNA.对96例HBV感染者的配偶婚前注射乙肝疫苗(HBVV)和/或高效价乙肝免疫球蛋白(HBIG);对46例HBV感染的孕妇及其新生儿采用HBVV和HBIG行母婴阻断;2年后检测所有被观察者的血清HBV-M.结果示男性HBV感染者的配偶HBV感染率较高(19.9%),而女性感染者的子女HBV感染率较高(36.4%);婚前注射HBVV可使HBV感染率明显降低;采用HBIG加HBVV母婴阻断可显著降低新生儿的HBV感染率。
Current status in implementing "The guidelines for prevention and treatment for hypertension in China"by professionals of primary health care in Beijing
Authors: 刘姝倩, 姚崇华, 任京媛, 胡先之, 刘力生
Journal: BMJ (2004)

目的 分析 在北京基层医院的执行现状,为 的推广实施提出具体的措施和建议,以提高基层医生高血压防治的整体水平.方法采用系统随机抽样方法,对400位北京市城乡基层医生进行问卷调查.结果 的总体执行状况城区好于乡镇;对 的知晓率为87.8%,培训率29.0%,持有率为55.5%,知识得分及格率44.0%;知识和行为与 培训有关,主要在药物和非药物治疗的知识和行为上.结论应提高 持有率和培训率,改进培训的方法和内容,将重点放在药物和非药物治疗的技能上。
Fat embolism syndrome:clinical revciew treatment
Authors: 魏雁林, 赵如青
Journal: BMJ (2004)

脂肪栓塞综合征(FES)是骨折后,特别是长管状骨骨折、骨盆骨折、多发骨折后的严重并发症之一,以意识障碍、呼吸困难、皮肤出血点、进行性低氧血症为特征.在骨折创伤死亡病例中行病理检查,FES发生率高达90%～100%[1].骨折后的FES发生率各家报道不一,平均发生率为7%左右[1],长管状骨骨折为0.9%～3.5%,骨盆骨折为5%～10%[2].FES病死率高,可达10%～15%[3],也有报道高达50%[4],故在临床治疗护理中应特别引起重视.将近年来对本病的临床观察及治疗综述如下。
Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM).
Authors: Stefania Oliva, Elisa Genuardi, Angelo Belotti, Pio Manlio Mirko Frascione, Monica Galli, Andrea Capra, Massimo Offidani, Federico Vozella, Renato Zambello, Daniel Auclair, Ilan Kirsch, Marina Ruggeri, Allison Jacob, Antonio Ledda, Paolo Corradini, Milena Gilestro, Elena Zamagni, Pellegrino Musto, Mario Boccadoro, Francesca Gay
Journal: Journal of Clinical Oncology (2020)

8533 Background: The role of MRD by MFC and NGS is well known in MM, with few data on the concordance of the two techniques. We analyzed and compared MRD data from the FORTE trial both by MFC and NGS. Methods: Newly diagnosed MM patients (pts) ≤65 years were randomized to: carfilzomib, lenalidomide, dexamethasone (KRd) induction-autologous stem cell transplant (ASCT) - KRd consolidation (KRd_ASCT); 12 KRd cycles (KRd12); carfilzomib, cyclophosphamide, dexamethasone (KCd) induction-ASCT-KCd consolidation (KCd_ASCT). Pts were then randomized to maintenance: lenalidomide alone or plus carfilzomib. MRD was assessed by 8-color second generation flow cytometry (sensitivity 10 −5 ) in pts with ≥very good partial response (VGPR) before maintenance. In a subgroup of these pts, next generation flow (NGF; sensitivity 10 −5 -10 −6 ) was performed. In ≥CR pts, MRD pre-maintenance was also assessed by NGS (Adaptive Biotechnologies; sensitivity 10 −5 -10 −6 ). Thus, both MFC and NGS evaluations were available only in ≥CR pts. 1-year sustained MRD negativity by MFC and NGS was also analyzed in pts with at least one sample available at least 1 year apart. Results: MFC and NGS data were available in 184/233 (79%) CR pts (66 KRd_ASCT, 67 KRd12 and 51 KCd_ASCT). Median age of this ≥CR population was 57 years (IQR 52-62), 13% had International Staging System (ISS) III and 27% high risk cytogenetics by FISH [either del(17p) or t(4;14) or t(14;16)]. Table reports MRD negativity rate by MFC and NGS at a cut-off of 10 −5 and 10 −6 among ≥CR negative pts in the 3 arms. NGS negativity at a cut-off 10 −6 was found in 36/133 (27%) ≥CR pts (for 51/184 CR pts 10 −6 sensitivity was not reached). In evaluable pts, 1-year sustained 10 −5 MRD negativity by MFC and NGS was superimposable (83%). We evaluated concordance of MRD results by the two techniques and observed agreement was 86% for MFC and NGS at 10 −5 evaluable samples (n: 335; r: 0.61) and 78% for MFC and NGS at 10 −6 evaluable samples (n: 56; r: 0.77). Conclusions: In pts who achieved ≥CR, similar rate of pre-maintenance 10 −5 negativity by MFC and NGS has been reached in each arm, with 83% pts maintaining 1-year MFC or NGS 10 −5 sustained MRD negativity. Concordance between MFC and NGS was good, particularly when the same sensitivity was reached. Longer follow up is needed to draw definitive conclusions. Clinical trial information: NCT02203643 . [Table: see text]
A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results.
Authors: Zev A. Wainberg, Minal A. Barve, Erika Paige Hamilton, Andrew Jacob Brenner, Frances Valdes, Monica M. Mita, Valeria González, Banmeet S. Anand, Christine Burnett, Joshua Pelham, Roger J. Waltzman, Thomas Strack, Brian A. Van Tine
Journal: Journal of Clinical Oncology (2020)

e15567 Background: Engineered toxin bodies (ETBs), composed of a Shiga-like Toxin A subunit genetically fused to antibody-like binding domains, can force receptor internalization, self-route through intracellular compartments to the cytosol, and induce potent cell-kill via the enzymatic and permanent inactivation of ribosomes. MT-5111, a de-immunized 55 kD ETB targeting HER2 in solid tumors, binds to an epitope distinct from and non-competitive with trastuzumab and pertuzumab. Methods: The primary objective is to determine the maximum tolerated dose (MTD) of MT-5111 monotherapy in adults with advanced HER2+ solid tumors. Secondary objectives are pharmacokinetics, efficacy, and immunogenicity. Part 1 will identify the MTD via MT-5111 dose escalation (0.5, 1.0, 2.0, 3.0, 4.5, 6.75, 10 µg/kg/dose) according to a modified 3+3 design. Part 2 will further evaluate the safety of MT-5111 at the recommended phase 2 dose (RP2D) in 3 separate cohorts of subjs with a HER2 immunohistochemistry score ≥2 in a metastatic lesion of primary breast, gastroesophageal, or other cancers. All subjs receive MT-5111 as a 30-minute IV infusion on Days 1, 8, and 15 of each 21-day treatment (tx) cycle (C) until disease progression, unacceptable toxicity, death, or withdrawn consent. Details can be found on clinicaltrials.gov (NCT04029922). Results: The first cohort (0.5 µg/kg/dose) enrolled 4 subjs (metastatic breast cancer, n = 2; metastatic cholangiocarcinoma, n = 2). Three subjs were female and the mean age was 69 years (median 65, range 64-78). Subjs received a mean of 5 prior lines of therapy (median 4.5, range 3-8). Three subjs completed C1 of tx without dose-limiting toxicities; 1 subj was inevaluable. Two subjs had progressive disease in C2. A total of 23 AEs occurred in 4 subjs; all were grade (G) 1-2 except one G3 event of hypertension in a subj with a history of hypertension. There were 2 tx-related AEs (G1 chills; G2 aspartate aminotransferase increased in the setting of progressive liver metastases). There was 1 serious, non-tx-related AE (G2 dyspnea) that occurred in the inevaluable subj. No cardiac AEs were noted, nor clinically significant changes in cardiac biomarkers, an important safety parameter given non-human primate toxicity. Conclusions: MT-5111 appears to be well tolerated at the lowest dose with no apparent cardiotoxicity to date. Drug concentrations are expected to be below the level required for in vitro tumor cell killing. Safety and efficacy data from subsequent dose escalation cohorts are expected by May 2020. Clinical trial information: NCT04029922.
过量服用尼群地平致低血压心动过缓高血糖一例
Authors: 陈炎, 陈亚蓓, 陶荣芳
Journal: BMJ (2007)

患者女,22岁.于2005年10月12日20:30因低血压4 h转至本院急救中心.当日午后患者感觉不适离开工作岗位回家,16:00家人发现其卧床不起,面色苍白,经再三追问获悉,患者企图自杀于中午吞服了尼群地平片116片(共1160 mg).送至附近诊所时,血压80/62 mm Hg(1 mm Hg=0.133 kPa)。